Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE combined with apatinib and carrelizumab for intermediate-stage hepatocellular carcinoma
ChiCTR2000040408Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib and camrelizumab in hepatocellular carcinoma (HCC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Progression-free survival. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
Rivoceranibcamrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000040408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040408.